Eun Ok Kim
About Eun Ok Kim
Eun Ok Kim is a scientist currently employed at Sonoma Biotherapeutics since 2022. With a background in cell biology and extensive experience in various research roles, Kim has worked at several notable companies in the biotechnology sector.
Work at Sonoma BioTherapeutics
Eun Ok Kim has been employed as a Scientist at Sonoma BioTherapeutics since 2022. In this role, Kim contributes to the development of innovative biotherapeutic solutions. The position involves conducting research and experiments that align with the company's mission to advance therapeutic options in the biopharmaceutical field.
Previous Experience in Biopharmaceutical Research
Prior to joining Sonoma BioTherapeutics, Eun Ok Kim held several positions in the biopharmaceutical industry. Kim worked as a Lab Fellow at Second Genome Inc. from 2016 to 2022, and as a Senior Research Associate at Bioseek from 2014 to 2016. Kim also served as a Research Associate at Principia Biopharma from 2011 to 2012 and at Rigel Pharmaceuticals Inc. from 2004 to 2005. Additionally, Kim was an Associate Research Scientist at Exelixis from 2005 to 2011 and a Scientific Associate at Novartis Institutes for BioMedical Research from 2012 to 2014.
Education and Expertise
Eun Ok Kim earned a Bachelor of Science degree in Cell Biology from the University of California, Davis, completing the program from 2000 to 2004. This educational background provides a strong foundation in biological sciences, which supports Kim's extensive experience in research roles within the biopharmaceutical sector.
Career Timeline
Eun Ok Kim's career in the biopharmaceutical industry spans over 18 years. Starting as a Research Associate at Rigel Pharmaceuticals Inc. in 2004, Kim progressed through various roles, including Associate Research Scientist at Exelixis and Scientific Associate at Novartis Institutes for BioMedical Research. The timeline reflects a consistent focus on research and development in the field, culminating in the current position at Sonoma BioTherapeutics.